Effective October 2017, Kv1.3 Therapeutics, Inc. began to issue external communications and press releases.
Previous press releases from KPI Therapeutics, Inc are included for information.

KPI Therapeutics Presents New Dalazatide Data Again Demonstrating Positive Response in Lupus

Kv1.3 on T cells detected for the first time in urine of lupus patients

Download Abstract

SEATTLE, May 22, 2017 – KPI Therapeutics Inc., a clinical stage biotechnology company presented new study data supporting the potential effectiveness of KPI’s lead drug dalazatide in lupus. The results were presented this weekend at the American College of Rheumatology’s Pediatric Rheumatology Symposium 2017 in Houston, TX. by study leader Dr. Anne Stevens, a researcher at the Seattle Children’s Research Institute.

Lupus is an autoimmune disease which causes kidney inflammation and tissue damage. Effector memory T cells appear to play an important role in lupus by secreting inflammatory mediators (cytokines) that perpetuate inflammation. Dalazatide is a potent and specific inhibitor of Kv1.3 potassium channels on activated effector memory T cells. Inhibition of the Kv1.3 channels on these T cells has become an important strategy for treating autoimmune disorders. Dalazatide blocks just a subset of T cells, leaving the rest of the immune system intact.

In a previous study, Dr. Stevens showed that the T cells in the blood of lupus patients express higher levels of Kv1.3. Now for the first time the new data showed Kv1.3 on T cells in the urine of lupus patients.

“These white blood cells in the urine come directly from the kidneys, so this data further supports the premise that inflammatory cells in the kidney can be targeted by dalazatide. This could also be a method to help identify patients that may respond to dalazatide treatment,” Dr. Stevens stated. “These findings also support further clinical advancement of dalazatide for the treatment of this disease for which current therapies are toxic and lead to global immune-suppression.”

Link to Abstract

About KPI Therapeutics

KPI Therapeutics is a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity using its novel Kv1.3 channel blocker based platform. Its lead drug dalazatide is being clinically advanced for Inclusion Body Myositis, an orphan disease as well as lupus. Our autoimmune platform molecules are also being developed for new therapies to address atopic dermatitis and uveitis. For more information about KPI please visit our website: www.kpitherapeutics.com

About Dalazatide

Dalazatide is a potential new therapy for systemic autoimmune diseases. It has completed a Phase 1b clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA) and was the first specific Kv1.3 inhibitor advanced into human clinical trials. It is Phase 2 ready. Dalazatide is being advanced and studied as a treatment for multiple autoimmune diseases including inclusion body myositis, lupus, ANCA vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, and asthma.

NOTICE: This document contains certain forward-looking statements, including development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Effective October 2017, Kv1.3 Therapeutics, Inc. began to issue external communications and press releases.
Previous press releases from KPI Therapeutics, Inc are included for information.

KPI Therapeutics Presents Updated, Positive Data Demonstrating Efficacy of KPI-150 Against Atopic Dermatitis

New data shows KPI 150’s effective skin penetration

Download Poster

SEATTLE, April 27, 2017 – KPI Therapeutics Inc., a clinical stage biotechnology company today presented updated data demonstrating its KPI-150 drug has potential therapeutic benefit in atopic dermatitis and other dermatologic inflammatory diseases when administered topically in animal models. The new KPI-150 data also demonstrated for the first time effective skin penetration in the areas of inflammation. The results were announced at the Society for Investigative Dermatology 76^thAnnual Meeting in Portland, OR by KPI’s Vice President, Scientific Affairs Dr. Chelsea Olsen.

KPI-150 is a potent and specific inhibitor of Kv1.3 potassium channels on activated effector memory T cells, which are key drivers of autoimmunity and are pathogenic in many autoimmune diseases. Inhibition of the Kv1.3 channels on these T cells has become an important strategy for treating autoimmune disorders. One key benefit of KPI-150 is that it blocks just a subset of T cells, leaving the rest of the immune system intact so that the body’s normal infection fighting ability is maintained.

“In the updated data we are presenting here, topical administration of KPI-150 in an animal model of dermatitis demonstrated significant reduction in T-cell infiltration and inflammation along with reduction in ear thickness,” said Dr. Olsen. “Even in an unoptimized formulation, KPI-150 shows significant skin penetration and efficacy in this model supporting the development of this novel Kv1.3 inhibitor for inflammatory skin diseases including atopic dermatitis,” Dr. Olsen concluded.

Atopic Dermatitis is a chronic inflammatory autoimmune skin disease that affects over 15 million people in the USA alone. More than half of those patients are under the age of 20. The current treatment options such as moisturizers and corticosteroids only address the symptoms of the disease and stronger immunosuppressive drugs can have debilitating side effects.

LINK TO POSTER

About KPI Therapeutics

KPI Therapeutics is a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity using its novel Kv1.3 channel blocker based platform. Its lead drug, dalazatide is being clinically advanced for Inclusion Body Myositis, (IBM) an orphan disease, and for lupus. Our autoimmune platform molecules are also being developed for new therapies to address atopic dermatitis and uveitis. For more information about KPI’s pipeline please visit our website:www.kpitherapeutics.com

About KPI-150, KPI-190, and dalazatide

KPI-150 is a novel Kv1.3 inhibitor from the same family of molecules in KPI Therapeutics’ autoimmune platform which includes KPI-190 and dalazatide. Preclinical and clinical data have shown that these drugs are selective and potent blockers of the voltage-gated Kv1.3 potassium channel – a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. KPI-150 is in development for atopic dermatitis (also commonly referred to as eczema) a medical condition of the skin associated with severe itching, redness, scaling, and flaking. About half of all atopic dermatitis sufferers are under the age of 18. In both children and in adults, this disease is associated with sleep disturbances, more days of lost work or school, and an adverse quality of life.

KPI-190 is also a novel Kv1.3 inhibitor in development as a therapy for eye diseases such dry eye syndrome and uveitis which can cause irreversible vision damage. Uveitis is one of the leading causes of blindness in the US and remains a significant unmet need. There are over 680,000 uveitis patients in the US with few treatment options. More than 13 million people a year in the US are affected by Dry Eye disease.

Dalazatide, is a potential new therapy for systemic autoimmune diseases. It has completed a Phase 1b clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA) as in KPI-150 and KPI-190. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. It is Phase 2 ready. Dalazatide is being studied as a treatment for multiple autoimmune diseases including lupus, myositis, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, and asthma.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Effective October 2017, Kv1.3 Therapeutics, Inc. began to issue external communications and press releases.
Previous press releases from KPI Therapeutics, Inc are included for information.

KPI Therapeutics Presents New Positive Data Demonstrating Efficacy of KPI-150 Against Atopic Dermatitis

Download PDF

SEATTLE, Nov. 16, 2016 – KPI Therapeutics Inc., a clinical stage biotechnology company today presented new data which demonstrated that its KPI-150 peptide has potential therapeutic benefit in atopic dermatitis and other dermatologic inflammatory diseases when administered topically in animal models. The results were announced at the 2nd Annual Inflammatory Skin Diseases Summit at the New York Academy of Medicine by KPI’s Vice President, Scientific Affairs, Chelsea Olsen, Ph.D.

KPI-150 is a potent and specific peptide inhibitor of Kv1.3 potassium channels on activated effector memory T-cells which are key drivers of autoimmunity and are pathogenic in many autoimmune diseases. Inhibition of the Kv1.3 channels on these T-cells has become an important strategy for treating autoimmune disorders. One key benefit of KPI-150 is that it blocks just a subset of T-cells, leaving the rest of the immune system intact so that the body’s normal infection fighting ability is maintained.

“My lab has shown that in human studies, skin lesions from patients with atopic dermatitis show high levels of Kv1.3, suggesting a possible relevance for KPI-150 in atopic dermatitis,” said co-investigator on this study Dr. Emma Guttman-Yassky, Vice Chair of the Department of Dermatology, Professor of Dermatology & Immunology and Director of the Center for Excellence in Eczema, at the Icahn School of Medicine at Mount Sinai Medical Center in New York.

“In the data we are presenting here, topical administration of KPI-150 in a model of dermatitis demonstrated significant reduction in T-cell infiltration and inflammation. These results are very encouraging and show that KPI-150 may offer a new treatment option for the millions of patients with atopic dermatitis, especially for those patients where maintaining a normal immune function is of significant importance,” said Dr. Olsen.

Atopic Dermatitis is a chronic inflammatory autoimmune skin disease that affects over 15 million people in the USA alone. More than half of those patients are under the age of 20. The current treatment options such as moisturizers and corticosteroids only address the symptoms of the disease and stronger immunosuppressive drugs can have debilitating side effects.

Link to poster

About KPI Therapeutics

KPI Therapeutics is a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity. KPI leads an alliance of development partners under a common purpose to drive focused and efficient drug development. KPI partners include Kineta, Inc, Chimera Biotec, Life Chemicals, MPI Research, Medical Marketing Economics, CoMotion, the University Of Washington School Of Medicine and the Alliance for Children’s Therapeutics, which includes Seattle Children’s Research Institute. For more information about KPI please visit our website:www.kpitherapeutics.com

About KPI-150, KPI-190, and dalazatide

KPI-150 is a novel Kv1.3 inhibitor from the same family of molecules in KPI Therapeutics’ autoimmune platform, which includes KPI-190 and dalazatide. Preclinical and clinical data have shown that these drugs are selective and potent blockers of the voltage-gated Kv1.3 potassium channel – a key channel in the activation of effector-memory T-cells. Effector memory T-cells are implicated in the pathology of many autoimmune diseases. KPI-150 is in development for atopic dermatitis (also commonly referred to as eczema) a medical condition of the skin associated with severe itching, redness, scaling, and flaking. About half of all atopic dermatitis sufferers are under the age of 20. In both children and in adults, this disease is associated with sleep disturbances, more days of lost work or school, and an adverse quality of life.

KPI-190 is also a novel Kv1.3 inhibitor in development as a therapy for eye diseases such as dry eye syndrome and uveitis which can cause irreversible vision damage. Uveitis is one of the leading causes of blindness in the US and remains a significant unmet need. There are over 680,000 uveitis patients in the US with few treatment options. More than 13 million people a year in the US are affected by dry eye disease.

Dalazatide, is a potential new therapy for systemic autoimmune diseases. It has completed a Phase 1b clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA) as in KPI-150 and KPI-190. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. It is Phase 2 ready. Dalazatide is being studied as a treatment for multiple autoimmune diseases including lupus, myositis, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, and asthma.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Effective October 2017, Kv1.3 Therapeutics, Inc. began to issue external communications and press releases.
Previous press releases from KPI Therapeutics, Inc are included for information.

KPI Therapeutics Invited to Present Positive Data on KPI-150 as a Potential New Therapy for Atopic Dermatitis at Skin Disease Conference

Download PDF

SEATTLE, Oct. 27, 2016 – KPI Therapeutics Inc., a clinical stage biotechnology company today announced it has been invited to present updated data on its KPI-150 program, a topical Kv1.3 inhibitor, as a potential new therapy against atopic dermatitis at the 2nd Annual Inflammatory Skin Diseases Summit at the New York Academy of Medicine, Nov. 16-19 in New York City. KPI’s Vice-President, Scientific Affairs, Chelsea Olsen, Ph.D. will present data showing that KPI-150 is effective against atopic dermatitis in animal models when applied topically. KPI-150 may also be effective against other dermatologic inflammatory diseases. Fifteen million Americans suffer from atopic dermatitis. Treatment options for this disease are limited, and long-term management solutions are lacking. KPI-150 is a new treatment modality with a novel mechanism of action that is not associated with the broad immunosuppression of existing agents.

About KPI Therapeutics

KPI Therapeutics is a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity. KPI leads an alliance of development partners under a common purpose to drive focused and efficient drug development. KPI partners include Kineta Inc, Chimera Biotec, Life Chemicals, MPI Research, Medical Marketing Economics, CoMotion, the University Of Washington School Of Medicine and the Alliance for Children’s Therapeutics, which includes Seattle Children’s Research Institute. For more information about KPI please visit our website:www.kpitherapeutics.com

About KPI-150, KPI-190, and dalazatide

KPI-150 is a novel Kv 1.3 inhibitor from the same family of molecules in KPI Therapeutics’ autoimmune platform which includes KPI-190 and dalzatide. Preclinical and clinical data have shown that these drugs are selective and potent blockers of the voltage-gated Kv1.3 potassium channel – a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. KPI-150 is in development for atopic dermatitis (also commonly referred to as eczema) a medical condition of the skin associated with severe itching, redness, scaling, and flaking. About half of all atopic dermatitis sufferers are under the age of 18. In both children and in adults, this disease is associated with sleep disturbances, more days of lost work or school, and an adverse quality of life.

KPI-190 is also a novel Kv 1.3 inhibitor in development as a therapy for eye diseases such dry eye syndrome and uveitis which can cause irreversible vision damage. Uveitis is one of the leading causes of blindness in the US and remains a significant unmet need. There are over 680,000 uveitis patients in the US with few treatment options. More than 13 million people a year in the US are affected by Dry Eye disease.

Dalazatide, is a potential new therapy for systemic autoimmune diseases. It has completed a Phase 1b clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA) as in KPI-150 and KPI-190. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. It is Phase 2 ready. Dalazatide is being studied as a treatment for multiple autoimmune diseases including lupus, myositis, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, and asthma.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Effective October 2017, Kv1.3 Therapeutics, Inc. began to issue external communications and press releases.
Previous press releases from KPI Therapeutics, Inc are included for information.

Alliance for Children’s Therapeutics (ACT) Presents Dalazatide Data Demonstrating Positive Response in Lupus

Biomarkers correlate with disease activity and response to therapy

Download PDF

Download Poster

Seattle, WA, June 10, 2016 – The Alliance for Children’s Therapeutics today presented positive, updated data from an ex vivo study using KPI’s Therapeutics/Kineta’s lead drug dalazatide for children and teens with lupus nephritis. The results were presented at the European League Against Rheumatism’s 17th Annual Congress in London. Dr. Anne Stevens, a researcher at the Seattle Children’s Research Institute, is leading the study and presented the work at the congress.

Lupus nephritis is an autoimmune disease which causes kidney inflammation and damage. Current medications are effective in reducing some of the inflammation associated with the disease, but they also suppress normal functions of the immune system, an undesirable side effect that is particularly problematic in children.

In particular, effector memory T cells associated with development of other autoimmune diseases such as psoriasis, inflammatory bowel diseases and rheumatoid arthritis appear to play an important role in lupus nephritis. T cells secrete inflammatory mediators (cytokines) that cause tissue damage and inflammation. T cells and B cells can amplify inflammatory responses thereby causing damage to the otherwise healthy tissue.

“New study data shows that patients with active lupus nephritis express higher levels of the Kv 1.3 channel, the target of dalazatide, than do patients with inactive disease or healthy volunteers,” said Dr. Stevens. “T cells from patients with active lupus are sensitive to blockade by dalazatide, demonstrating ex vivo efficacy of the drug, and provide data to support the design of a clinical trial in patients with lupus,” Dr. Stevens added.

“Lupus patients are in urgent need of novel and more effective therapies,” said Dr. Charles Magness, President and CEO of KPI Therapeutics. “We are very encouraged by the positive effect dalazatide has demonstrated in this study and are working to advance dalazatide into lupus and lupus nephritis clinical trials.”

The updated data also demonstrated that dalazatide can decrease a group of cytokines functioning as biomarkers associated with active lupus disease. Importantly, these results show that dalzatide has the ability to suppress these cytokines which are associated with disease inflammation and damage to lupus patients to a degree similar to traditional but toxic therapies such as cyclosporine A.

About dalazatide

Dalazatide completed a Phase 1B clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA). Preclinical and clinical data have shown that dalazatide is a selective and potent blocker of the voltage-gated Kv1.3 potassium channel – a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. Dalazatide is being studied as a potential therapy for autoimmune diseases including lupus, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, and asthma. Dalazatide is being developed jointly with Kineta Inc.

About KPI Therapeutics

KPI Therapeutics is a clinical stage biotechnology company which develops first in class therapies for unmet medical needs in autoimmunity and chronic pain. KPI leads an alliance of development partners under a common purpose to drive focused and efficient drug development. KPI partners include Kineta, Inc, Chimera Biotec, Life Chemicals, MPI Research, Medical Marketing Economics, CoMotion, the University Of Washington School Of Medicine and the Alliance for Children’s Therapeutics which includes Seattle Children’s Research Institute. With its lead development partner Kineta, Inc, KPI is advancing the development of dalazatide (systemic autoimmune diseases including lupus) and CSP conopeptides (chronic pain). For more information about KPI please visit our website:www.kpitherapeutics.com

About Kineta

Kineta, Inc.is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website,www.kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, successful completion of clinical testing, and achievement of regulatory approval. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Effective October 2017, Kv1.3 Therapeutics, Inc. began to issue external communications and press releases.
Previous press releases from KPI Therapeutics, Inc are included for information.

KPI Therapeutics’ BIO Presentation to Highlight First Clinical Development Success of Kv 1.3 Inhibitor Dalazatide in Autoimmune Diseases

Download PDF

Seattle, WA June 2, 2016 – KPI Therapeutics, a clinical stage biotechnology company today announced that it will give a company presentation at the Biotechnology Innovation Organization’s (BIO) annual meeting in San Francisco on June 6, at 3:15 pm, Theater 2. KPI President and CEO Dr. Charles Magness will present a corporate overview of its clinical programs including its Kv 1.3 inhibitors for autoimmune diseases which include dalazatide, KPI-150 and KPI-190, as well as future clinical and business milestones.

Inhibitors of the Kv 1.3 channel have been pursued as a target of pharmaceutical development for more than 15 years due to its role in numerous autoimmune diseases including lupus, inflammatory bowel diseases, atopic dermatitis, and uveitis. KPI and lead development partner Kineta are the first to bring dalazatide, a Kv 1.3 inhibitor into clinical development and have successfully completed three Phase 1 clinical trials demonstrating its safety and proof of concept efficacy.

The BIO meeting is the largest annual gathering biotech executives, researchers and investors in the world.

About dalazatide

Dalazatide completed a Phase 1B clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA). Preclinical and clinical data have shown that dalazatide is a selective and potent blocker of the voltage-gated Kv1.3 potassium channel – a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. Dalazatide is being studied as a potential therapy for autoimmune diseases including lupus, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, and asthma. Dalazatide is being developed jointly with Kineta Inc.

About KPI Therapeutics

KPI Therapeutics is a clinical stage biotechnology company which develops first in class therapies for unmet medical needs in autoimmunity and chronic pain. KPI leads an alliance of development partners under a common purpose to drive focused and efficient drug development. KPI partners include Kineta, Inc, Chimera Biotec, Life Chemicals, MPI Research, Medical Marketing Economics, CoMotion, the University Of Washington School Of Medicine and the Alliance for Children’s Therapeutics which includes Seattle Children’s Research Institute. With its lead development partner Kineta, Inc, KPI is advancing the development of dalazatide (systemic autoimmune diseases including lupus) and CSP conopeptides (chronic pain). For more information about KPI please visit our website:www.KPITherapeutics.com

About Kineta

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website:www.kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, successful completion of clinical testing, and achievement of regulatory approval. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Effective October 2017, Kv1.3 Therapeutics, Inc. began to issue external communications and press releases.
Previous press releases from KPI Therapeutics, Inc are included for information.

KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus

Download PDF

Seattle, WA May 23, 2016 – KPI Therapeutics, a clinical stage biotechnology company today announced it will present updated data on the effects of its lead drug dalazatide in an ex-vivo study in lupus at the European League Against Rheumatism conference on June 9th in London. Dr. Anne Stevens, a researcher at Seattle Children’s Research Institute will present the poster study. Lupus is a chronic, autoimmune disease with limited treatment options.

KPI’s President and CEO Dr. Charles Magness will be making a full corporate presentation at the Biotechnology Innovation Organization (BIO) conference on June 6th in San Francisco. Dr. Magness will report on KPI’s clinical and business milestones.

About dalazatide

Dalazatide completed a Phase 1B clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA). Preclinical and clinical data have shown that dalazatide is a selective and potent blocker of the voltage-gated Kv1.3 potassium channel – a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. Dalazatide is being studied as a potential therapy for autoimmune diseases including lupus, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, and asthma. Dalazatide is being developed jointly with Kineta Inc.

About KPI Therapeutics

KPI Therapeutics is a clinical stage biotechnology company which develops first in class therapies for unmet medical needs in autoimmunity and chronic pain. KPI leads an alliance of development partners under a common purpose to drive focused and efficient drug development. KPI partners include Kineta, Inc, Chimera Biotec, Life Chemicals, MPI Research, Medical Marketing Economics, CoMotion, the University Of Washington School Of Medicine and the Alliance for Children’s Therapeutics which includes Seattle Children’s Research Institute. With its lead development partner Kineta, Inc, KPI is advancing the development of dalazatide (systemic autoimmune diseases including lupus) and CSP conopeptides (chronic pain). For more information about KPI please visit our website:www.kpitherapeutics.com

About Kineta

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website,www.kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, successful completion of clinical testing, and achievement of regulatory approval. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Effective October 2017, Kv1.3 Therapeutics, Inc. began to issue external communications and press releases.
Previous press releases from KPI Therapeutics, Inc are included for information.

KPI Therapeutics Presents Dalazatide Plaque Psoriasis Data at Dermatology Conference

KPI-150 Kv1.3 inhibitor from dalazatide family under development for atopic dermatitis with promising new data

SEATTLE, WA May 12, 2016 – KPI Therapeutics, a clinical-stage biotechnology company, today presented plaque psoriasis data from its dalazatide Phase 1B clinical trial at the 75th Society for Investigative Dermatology Conference in Scottsdale, AZ. KPI’s Dr. Chelsea Olsen presented the data on dalazatide, a first-in-class peptide inhibitor of the Kv1.3 potassium channel implicated in many autoimmune diseases.

Using novel compounds from the dalazatide family, KPI is also developing a topical biologic Kv1.3 inhibitor, KPI-150, for atopic dermatitis. This agent targets the immune cells which cause autoimmune diseases.

“The results from our Phase 1B clinical trial in psoriasis validated the mechanism of action of dalazatide in a prototypical T cell mediated autoimmune disease and demonstrated its potential as a first-in-class Kv1.3 inhibitor. With the encouraging proof-of-concept efficacy data we saw in this trial there is potential for breakthrough treatments in a number of other autoimmune diseases,” said Dr. Olsen. “Recent data shows that there is even higher Kv1.3 expression in atopic dermatitis lesional skin than in psoriasis lesional skin, making atopic dermatitis a promising target for treatment with KPI-150.

“The psoriasis trial also demonstrated that not only is dalazatide safe and well tolerated, but that it can improve skin lesions in individuals with plaque psoriasis by specifically inhibiting effector memory T cell activation and decreasing the levels of inflammatory cytokines,” Dr. Olsen added.

Atopic dermatitis is a chronic inflammatory autoimmune disease which causes itching, scratching, scaling, insomnia and loss of skin surface. Current cases of atopic dermatitis in the US exceed 15 million, with over half of these cases in people less than 20 years old.

POSTER

About dalazatide

Dalazatide completed a Phase 1B clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA). Preclinical and clinical data have shown that dalazatide is  selective and potent blocker of the voltage-gated Kv1.3 potassium channel – a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. Dalazatide is being studied as a potential therapy for autoimmune diseases including lupus, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, and asthma. Dalazatide is being developed jointly with Kineta Inc.

About KPI-150

KPI-150 is a compound from the dalazatide family that also blocks the Kv 1.3 channel. KPI is developing this agent as a topical cream for atopic dermatitis, psoriasis and other dermatological complications associated with inflammatory diseases. Chronically activated TEM cells in atopic dermatitis are the target of KPI-150. A robust safety database exists for KPI compounds.

ABOUT KPITHERAPEUTICS

KPI Therapeutics is a clinical stage biotechnology company which develops first in class therapies for unmet medical needs in autoimmunity and chronic pain. KPI leads an alliance of development partners under a common purpose to drive focused and efficient drug development. KPI partners include Kineta, Inc, Chimera Biotec, Life Chemicals, MPI Research, Medical Marketing Economics, CoMotion, the University Of Washington School Of Medicine and the Alliance for Children’s Therapeutics which includes Seattle Children’s Research Institute. With its lead development partner Kineta, Inc, KPI is advancing the development of dalazatide (systemic autoimmune diseases including lupus) and CSP conopeptides (chronic pain). For more information about KPI please visit our website: kpitherapeutics.com.

ABOUT KINETA

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune  diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.kinetabio.com.

###
NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, successful completion of clinical testing, and achievement of regulatory approval. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Effective October 2017, Kv1.3 Therapeutics, Inc. began to issue external communications and press releases.
Previous press releases from KPI Therapeutics, Inc are included for information.

KPI Therapeutics to Present Dalazatide Plaque Psoriasis Data at Dermatology Conference

KPI-150 Kv 1.3 inhibitor from dalazatide family under development for atopic dermatitis

SEATTLE, WA April 18, 2016 – KPI Therapeutics, a clinical stage biotechnology company, has been invited to present plaque psoriasis data from its recent dalazatide Phase 1B clinical trial at the 75th Society for Investigative Dermatology Conference on May 11 in Scottsdale, AZ. KPI’s Dr. Chelsea Olsen will present the data on dalazatide, a first-in-class peptide inhibitor of the Kv 1.3 potassium channel implicated in many autoimmune diseases.

Using novel compounds from the dalazatide family, KPI is developing topical biologic Kv1.3 inhibitors for atopic dermatitis as well as for uveitis. These agents target the immune cells which cause autoimmune diseases.

Atopic dermatitis is a chronic inflammatory autoimmune disease which causes itching, scratching, scaling, insomnia and loss of skin surface. Current cases of atopic dermatitis worldwide reach over 66 million.

About dalazatide

Dalazatide (formerly ShK-186) completed a Phase 1b clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA). Preclinical and clinical data have shown that dalazatide is a selective and potent blocker of the voltage-gated Kv1.3 potassium channel – a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. Dalazatide is being studied as a potential therapy for autoimmune diseases including lupus, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, and asthma. Dalazatide is being developed jointly with Kineta Inc.

About KPI-150

KPI-150 is a compound from the dalazatide family that also blocks the Kv 1.3 channel. KPI is developing this agent as a topical cream for atopic dermatitis, psoriasis and other dermatological complications associated with inflammatory diseases. Chronically activated TEM cells in atopic dermatitis are the target of KPI-150. A robust safety database exists for KPI compounds.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, successful completion of clinical testing, and achievement of regulatory approval. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.